ClinicalTrials.gg
RecruitingNCT04776824B-CAREUpdated Nov 4, 2026

Swiss Cardiac Amyloidosis REgistry (Swiss-CARE)

An observational study in Amyloid Cardiomyopathy, sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 7 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Insel Gruppe AG, University Hospital Bern · Observational

How we know

From the registry’s dates

  • Started Feb 2001; still recruiting 25 years 9 months later.
Updated Nov 4, 2026Site recruiting status changed4 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Study summary

Cardiac transthyretin amyloidosis (ATTR), caused by ventricular depositions of misfolded transthyretin, results in an infiltrative cardiomyopathy, progressing from pronounced myocardial wall thickening, diastolic and systolic dysfunction to the development of terminal heart failure. Recently, treatment options for TTR amyloidosis have become available. However costs for therapy are enormous and previous trials were not able to differentiate between patients that might benefit from treatment and those without a need for treatment.

the investigators study aims to determine markers, as assessed by cardiac magnet resonance imaging (CMR) feature tracking (FT) and T1- and T2- mapping, that might reliably indicate disease severity and could help to identify patients that might benefit from (ongoing) TTR stabilization treatment.

Read the detailed description

Cardiac transthyretin amyloidosis (ATTR), the most common amyloidosis form with cardiac involvement, is caused by tissue deposition of misfolded TTR, a transport Protein for thyroxine and retinol. Ventricular depositions of amyloid fibrils results in an infiltrative cardiomyopathy, progressing from pronounced myocardial wall thickening, to diastolic and systolic dysfunction and finally chronic heart failure.

While treatment options are now available, it remains unclear how to monitor therapy response and disease progression. No makers have been identified that predict outcome prior to initiation of therapy, thus patient selection for therapy remains challenging.

The investigators study will address these issues and will provide systematically assessed CMR data before and over the course of 18 months after therapy initiation. Clinical and laboratory follow-up will be performed every 3-6 months. The investigators study is based on an open, uncontrolled, structured collection of retrospective and prospective data from all patients diagnosed with amyloidosis at the Inselspital Bern with the aim to follow patients undergoing therapy.

The investigators hypothesize that CMR feature tracking (FT) and measures of T1- and T2- mapping, such as extracellular volume (ECV) may better correlate with disease severity and help to identify patients likely to benefit from (ongoing) TTR stabilizing therapy. Beside standard CMR assessments, the investigators will use CMR feature tracking to quantify global and regional myocardial function. FT has proven to be an excellent predictor in various cardiomyopathies.

The proposed study will evaluate the potential of CMR to identify patients likely to benefit from therapy, monitor treatment response and balance individual patient benefit and health care cost.

02

Conditions studied

  • Amyloid Cardiomyopathy

Keywords

  • Cardiac Amyloidosis
  • Tafamidis
  • CMR feature tracking
  • Strain
  • T1 and T2 Mapping
  • Outcomes
03

In context

Amyloid Neuropathies, Familial

188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.

This study's planned enrollment of 300 is above the median of 233 across 92 observational studies indexed under Amyloid Neuropathies, Familial.

Browse Amyloid Neuropathies, Familial studies →

Lead sponsor

Insel Gruppe AG, University Hospital Bern is the lead sponsor of 744 studies on the registry; 182 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Confirmed diagnosis of amyloidosis w/wo cardiac involvement

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of amyloidosis w/wo cardiac involvement
  • General Consent

Exclusion criteria

Exclusion Criteria:

  • Inability to give consent or existence of a written or documented oral refusal of the data subject.\<18 years of age
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
300 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • Patients with confirmed amyloidosis

    Confirmed diagnosis of amyloidosis w/wo cardiac involvement

06

What researchers measure

Primary outcomes

  1. LV (left ventricle) and RV (right ventricle) function as assessed by CMR feature tracking as predictor for MACE (major adverse cardiac event)

    Global and regional longitudinal (%), circumferential (%) and radial (%) strain measurements are used to quantify LV and RV function before and after therapy initiation. MACE is defined as a composite of sustained ventricular tachycardia, hospitalization for heart failure and all-cause death.

    Time frame: 5 years

  2. LV and RV tissue characterization as assessed by T1 and T2 mapping as predictor for MACE

    Global and regional tissue characteristics are assessed by repetitive T1 and T2 mapping (global and regional T1 and T2 time (ms)) before and during therapy. MACE is defined as a composite of major cardiovascular endpoints listed above.

    Time frame: 5 years

  3. Late gadolinium enhancement as predictor for MACE

    Global and regional myocardial tissue is characterized by gadolinium contrast agent application. The presence and extent (% and total mass (g)) of late gadolinium enhancement is evaluated as a predictor for MACE.

    Time frame: 5 years

  4. Extracellular volume (ECV) as predictor for MACE

    ECV (%) as a marker of myocardial tissue remodelling is calculated from native and post-contrast T1 mapping and haematocrit before and during therapy.

    Time frame: 5 years

07

Study locations

7 of 7 sites recruiting
08

References and documents

Publications

  • Dobner S, Tawo S, Noti F, Wieser F, Grani C, Nitsche C, Reichlin T, Hunziker L, Haeberlin A. Indication and electrical performance of conventional, resynchronization, and conduction system pacing in transthyretin amyloid cardiomyopathy. Heart Rhythm O2. 2026 Mar 27;7(7):1289-1301. doi: 10.1016/j.hroo.2026.03.026. eCollection 2026 Jul. PubMed 42488169 ↗
  • Caobelli F, Popescu CE, Gozlugol N, Rominger A, Zangeneh FA, Munsch LH, Ciocca N, Stortecky S, Dobner S, Hundertmark M, Grani C. Correlation of global and regional quantitative 99m Tc-3,3-diphosphono-1,2 propanodicarboxylicacid single-photon emission computed tomography with echocardiography in patients with suspected transthyretin-related cardiomyopathy. Nucl Med Commun. 2026 Jun 1;47(6):638-643. doi: 10.1097/MNM.0000000000002138. Epub 2026 Mar 10. PubMed 41804669 ↗
  • Caobelli F, Gozlugol N, Bakula A, Rominger A, Schepers R, Stortecky S, Hunziker Munsch L, Dobner S, Grani C. Prognostic Value of [99mTc]Tc-DPD Quantitative SPECT/CT in Patients with Suspected and Confirmed Amyloid Transthyretin-Related Cardiomyopathy and Preserved Left Ventricular Function. J Nucl Med. 2024 Jun 3;65(6):944-951. doi: 10.2967/jnumed.123.266926. PubMed 38724281 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2001 (actual). Primary completion is estimated for May 2031, 362 months after the start.

Of 74 observational studies under Amyloid Neuropathies, Familial, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 120. This study's planned 362 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2021
First posted
Mar 2, 2021
StartActual
Feb 22, 2001
Primary completionEst.
May 1, 2031
CompletionEst.
May 1, 2031
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 4 sites removed. USB is now Recruiting
Show 4 added (4 Switzerland)
  • HUG · Geneva, Switzerland
  • LUKS · Lucerne, Switzerland
  • KSSG · Sankt Gallen, Switzerland
  • Stadtspital Triemli · Zurich, Switzerland
Show 4 removed
  • HUG · Genf, Switzerland
  • LUKS · Luzern, Switzerland
  • KSSG · St. Gallen, Switzerland
  • Stadtspital Triemli · Zürich, Switzerland
Nov 4, 2026
Publications
3 publications citing this study linked from PubMed, e.g. PubMed 42488169 ↗
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Publications 3 publications citing this study linked from PubMed, e.g. PubMed 42488169 ↗
    4 sites added, 4 sites removed. USB is now Recruiting
    Show 4 added (4 Switzerland)
    • HUG · Geneva, Switzerland
    • LUKS · Lucerne, Switzerland
    • KSSG · Sankt Gallen, Switzerland
    • Stadtspital Triemli · Zurich, Switzerland
    Show 4 removed
    • HUG · Genf, Switzerland
    • LUKS · Luzern, Switzerland
    • KSSG · St. Gallen, Switzerland
    • Stadtspital Triemli · Zürich, Switzerland
    + 1 other change: index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04776824
Responsible party
Sponsor
First posted
Mar 2, 2021
Start date
Feb 22, 2001
Primary completion
May 1, 2031 (estimated)
Completion
May 1, 2031 (estimated)
Last update
Nov 4, 2026

Study contacts

Christoph Gräni, MD, PhD
Contact
christoph.graeni@insel.ch
+41 31 632 4508
Moritz Hundertmark, MD, PhD
Contact
moritz.hundertmark@insel.ch
+41 31 63 2 40 86
Christoph Gräni, MD, PhD
principal investigator · Department of Cardiology, University Hospital Bern, Inselspital, Bern

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion